Print

BioAlliance Pharma Announces the Launch of Oravig® in the United States by Its New Partner, Vestiq Pharmaceuticals  
1/7/2013 10:21:27 AM

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the launch of Oravig® (known as Loramyc® in Europe) in the United States by its commercial partner, Vestiq Pharmaceuticals.
//-->